Local view for "http://purl.org/linkedpolitics/eu/plenary/2005-12-01-Speech-4-114"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2005-12-01"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"en"^^xsd:language2
lpv:document identification number	"en.20051201.30.4-114"2
lpv:hasSubsequent	lp_eu:2005-12-01-Speech-4-1152
lpv:speaker	lp:David Martin2
lpv:spoken text	". This regulation marks an important milestone for improving access to medicines in developing countries and it has my full support. It moves the EU beyond the current stalemate at the WTO regarding the granting of 'compulsory licences' to pharmaceutical products to combat diseases which afflict millions of people in the developing world. Its adoption means that the EU, the world's largest single market, can now provide not only the vital medicines needed by poor people at affordable prices, but can support the all-important development of local manufacture through the transfer of technology and know-how to public health systems in developing countries. I particularly endorse the attempts by the Rapporteur and Draftsman to extend the applicability of this regulation to non-WTO members, of which at least 40 are developing countries. Attempts to ensure that this new regulation can also allow for the important role of NGOs and UN agencies as providers of healthcare treatments also have my backing."@en1
lpv:spokenAs	substitute; Delegation to the EU-Bulgaria Joint Parliamentary Committee (2004-09-15--2006-12-31)3 member; PES (2004-07-20--2009-07-13)3 member; PETI (2004-10-13--2007-01-14)3 unknown; Labour Party (2004-07-20--2009-07-13)3 substitute; AGRI (2004-07-21--2006-03-15)3 member; Delegation for relations with Australia and New Zealand (2004-09-15--2007-03-13)3 member; INTA (2004-07-21--2007-01-14)3
lpv:unclassifiedMetadata	"David Martin (PSE ),"1 "in writing"1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph